CN102908312B - 抗乙肝病毒液体组合物 - Google Patents
抗乙肝病毒液体组合物 Download PDFInfo
- Publication number
- CN102908312B CN102908312B CN201210445175.4A CN201210445175A CN102908312B CN 102908312 B CN102908312 B CN 102908312B CN 201210445175 A CN201210445175 A CN 201210445175A CN 102908312 B CN102908312 B CN 102908312B
- Authority
- CN
- China
- Prior art keywords
- entecavir
- oral liquid
- test
- sodium diacetate
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 72
- 241000700721 Hepatitis B virus Species 0.000 title abstract description 4
- 229960000980 entecavir Drugs 0.000 claims abstract description 69
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 claims abstract description 69
- OPGYRRGJRBEUFK-UHFFFAOYSA-L disodium;diacetate Chemical compound [Na+].[Na+].CC([O-])=O.CC([O-])=O OPGYRRGJRBEUFK-UHFFFAOYSA-L 0.000 claims description 40
- 239000001632 sodium acetate Substances 0.000 claims description 40
- 235000017454 sodium diacetate Nutrition 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 150000008064 anhydrides Chemical class 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
- 238000002360 preparation method Methods 0.000 abstract description 17
- 238000002347 injection Methods 0.000 abstract description 3
- 239000007924 injection Substances 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 60
- 241000894006 Bacteria Species 0.000 description 37
- 239000000523 sample Substances 0.000 description 34
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 28
- 239000001963 growth medium Substances 0.000 description 27
- 239000000243 solution Substances 0.000 description 23
- 239000000203 mixture Substances 0.000 description 20
- 230000002421 anti-septic effect Effects 0.000 description 17
- 238000003756 stirring Methods 0.000 description 17
- 230000000844 anti-bacterial effect Effects 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- 235000002639 sodium chloride Nutrition 0.000 description 14
- 229960002668 sodium chloride Drugs 0.000 description 14
- 229920001817 Agar Polymers 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 239000008272 agar Substances 0.000 description 13
- 239000008121 dextrose Substances 0.000 description 11
- 235000003599 food sweetener Nutrition 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 239000003765 sweetening agent Substances 0.000 description 11
- 238000011081 inoculation Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000006150 trypticase soy agar Substances 0.000 description 7
- 241000228245 Aspergillus niger Species 0.000 description 6
- 241000222122 Candida albicans Species 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 229920001214 Polysorbate 60 Polymers 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 239000003443 antiviral agent Substances 0.000 description 5
- 229940095731 candida albicans Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 4
- 235000019658 bitter taste Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000007747 plating Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- -1 maltose alcohols Chemical class 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 238000009631 Broth culture Methods 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000010971 suitability test Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 108010050327 trypticase-soy broth Proteins 0.000 description 2
- 238000004879 turbidimetry Methods 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 244000071493 Iris tectorum Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003260 anti-sepsis Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940069078 citric acid / sodium citrate Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 208000019180 nutritional disease Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000021147 sweet food Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
时间(分钟) | 流动相A(%) | 流动相B(%) |
0 | 100 | 0 |
5 | 100 | 0 |
25 | 75 | 25 |
45 | 20 | 80 |
46 | 100 | 0 |
55 | 100 | 0 |
成分 | 量 | 功能 |
恩替卡韦(按无水物计) | 4.00g | 抗病毒剂 |
双乙酸钠 | 80.00g | 防腐剂 |
注射用水 | 加至80000ml | 溶剂 |
成分 | 加入量 | 功能 |
恩替卡韦 | 4.00g | 抗病毒剂 |
双乙酸钠 | 80.00 | 防腐剂 |
水 | 加水至80L | 溶剂 |
成分 | 功能 | |
恩替卡韦 | 15.00mg | 抗病毒剂 |
麦芽糖醇(Lycasin) | 195.00g | 增甜剂 |
对羟基苯甲酸甲酯 | 0.60g | 防腐剂 |
对羟基苯甲酸丙酯 | 0.084g | 防腐剂 |
樱桃水 | 1.50g | 调味剂 |
枸橼酸/枸橼酸钠 | 0.111g/0.72g | 缓冲剂 |
水 | 加至300ml(PH6.0) | 溶剂 |
成分 | 量 | 功能 |
恩替卡韦(按无水物计) | 4.00g | 抗病毒剂 |
氯化钠 | 360.00g | 防腐剂 |
注射用水 | 加至40000ml | 溶剂 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210445175.4A CN102908312B (zh) | 2011-11-10 | 2012-11-09 | 抗乙肝病毒液体组合物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110378118.4 | 2011-11-10 | ||
CN201110378118 | 2011-11-10 | ||
CN201210445175.4A CN102908312B (zh) | 2011-11-10 | 2012-11-09 | 抗乙肝病毒液体组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102908312A CN102908312A (zh) | 2013-02-06 |
CN102908312B true CN102908312B (zh) | 2014-06-04 |
Family
ID=47607053
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210445175.4A Expired - Fee Related CN102908312B (zh) | 2011-11-10 | 2012-11-09 | 抗乙肝病毒液体组合物 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN102908312B (zh) |
WO (1) | WO2013067769A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105722503A (zh) * | 2013-08-06 | 2016-06-29 | 东国制药株式会社 | 恩替卡韦微球及包含其的非口服给药用药学组合物 |
CN104083374A (zh) * | 2014-07-18 | 2014-10-08 | 石家庄创建医药科技有限公司 | 一种恩替卡韦口服液组合物 |
WO2021151122A1 (en) * | 2020-01-21 | 2021-07-29 | Thai Minh Pharmaceutial Joint Stock Company | Therapeutic compositions comprising sodium diacetate for cancer pain and metabolic abnormalities |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI275392B (en) * | 2002-04-08 | 2007-03-11 | Bristol Myers Squibb Co | Low dose liquid entecavir formulations and use |
CN1698623A (zh) * | 2005-03-30 | 2005-11-23 | 美德(江西)生物科技有限公司 | 无结晶型态的抗乙肝病毒药物分散组合物及其药物制剂 |
CN1330304C (zh) * | 2005-07-22 | 2007-08-08 | 中南大学湘雅二医院 | 一种抗氧化药物 |
CN102058521A (zh) * | 2009-11-17 | 2011-05-18 | 天津天成制药有限公司 | 一种含活性成分恩替卡韦经注射给药的制剂 |
CN101716137A (zh) * | 2009-12-10 | 2010-06-02 | 沈阳双鼎制药有限公司 | 恩替卡韦注射剂 |
-
2012
- 2012-11-09 CN CN201210445175.4A patent/CN102908312B/zh not_active Expired - Fee Related
- 2012-11-12 WO PCT/CN2012/001521 patent/WO2013067769A1/zh active Application Filing
Non-Patent Citations (2)
Title |
---|
双乙酸钠在调味品中的防腐作用;张林等;《中国酿造》;19981231(第5期);第3,16-18页 * |
张林等.双乙酸钠在调味品中的防腐作用.《中国酿造》.1998,(第5期),第3,16-18页. |
Also Published As
Publication number | Publication date |
---|---|
CN102908312A (zh) | 2013-02-06 |
WO2013067769A1 (zh) | 2013-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103156826B (zh) | 百秋李醇的用途 | |
NO335045B1 (no) | Farmasøytiske formuleringer av temozolomid, fremgangsmåter for fremstilling av disse, lyofilisert pulver av formuleringene, fremstilt artikkel inneholdende det lyofiliserte pulveret, og anvendelse av formuleringene som medikament | |
CN103479664B (zh) | 一种液态口服补液盐 | |
CN102405041A (zh) | 包含β-阻断剂的儿科溶液 | |
CN102908312B (zh) | 抗乙肝病毒液体组合物 | |
CN104323987B (zh) | 一种乙酰甲喹注射液及其制备方法 | |
CN103341114A (zh) | 草果油在制备治疗细菌感染性疾病的药物中的用途 | |
CN102058660B (zh) | 藿香油在制备治疗细菌感染性疾病的药物中的用途 | |
CN101695474A (zh) | 用于非经肠胃给药的长春氟宁医药组合物及其制备方法和用途 | |
CN101336903B (zh) | 注射用左旋奥硝唑磷酸二钠静脉制剂的制备方法 | |
CN104069061B (zh) | 一种含普乐沙福的注射用组合物及其制备方法和应用 | |
CN101618025B (zh) | 一种兽用盐酸多西环素冻干制剂及其制备方法 | |
CN111542330A (zh) | 肺炎链球菌感染的预防和/或治疗剂 | |
CN102525893B (zh) | 盐酸去氧肾上腺素注射液及其制剂工艺 | |
CN104434817A (zh) | 一种利拉鲁肽的注射用缓释微球制剂 | |
CN101642429A (zh) | 一种稳定的利福霉素钠注射液和利福霉素钠氯化钠(葡萄糖)注射液的制备方法 | |
CN108066338A (zh) | 预防和治疗需氧菌与厌氧菌混合感染时的新型抗生素组合物及其制备方法 | |
CN108670957A (zh) | 一种兽用酸化阿莫西林可溶性粉及其制备方法 | |
CN104721154B (zh) | 注射用谷氨酸诺氟沙星冷冻干燥粉针剂药物组合物 | |
CN105769756B (zh) | 一种富马酸西他沙星注射剂及其制备方法 | |
CN103239394A (zh) | 盐酸莫西沙星小容量注射液及其制备方法 | |
CN106860891A (zh) | 一种苯扎溴铵氯化钠冲洗液及其制备方法 | |
CN102716071B (zh) | 一种氟罗沙星甘露醇注射液及其制备方法 | |
CN107789320A (zh) | 一种氟维司群缓释注射液及其制备工艺 | |
CN101708155A (zh) | 利福霉素钠注射液及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
DD01 | Delivery of document by public notice |
Addressee: Chen Xiaohua Document name: Notification of Passing Preliminary Examination of the Application for Invention |
|
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: Chen Xiaohua Document name: Notification of Publication and of Entering the Substantive Examination Stage of the Application for Invention |
|
DD01 | Delivery of document by public notice |
Addressee: Lin Shanliang Document name: Notification of Passing Examination on Formalities |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171110 Address after: 100032 Beijing city Xicheng District Xishiku Street No. 31 Building No. 6 room 4347 Patentee after: Beijing Niubaiou Medical Technology Co Ltd Address before: 100023 Beijing Tongzhou District Light Industrial Park No. 5 building two layer Beijing Kangda Pharmaceutical Technology Co., Ltd. Patentee before: Chen Xiaohua |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140604 Termination date: 20201109 |
|
CF01 | Termination of patent right due to non-payment of annual fee |